ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
119.006,93
0,13%
S&P 500
5.836,22
0,16%
US Dollar vs BRL
6,1203
0,42%
Bitcoin
96.338,03
1,94%
Brent Oil
80,385
0,13%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Annexon Inc (ANNX)

  7. Annexon Inc (ANNX) Notícias

ANNX

Annexon (ANNX)

Annexon Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANNX
DataHoraFonteTítuloCódigoCompanhia
13/01/202510:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANNXAnnexon Inc
08/01/202519:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANNXAnnexon Inc
19/12/202418:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANNXAnnexon Inc
14/11/202420:46Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ANNXAnnexon Inc
14/11/202418:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANNXAnnexon Inc
08/11/202416:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ANNXAnnexon Inc
15/10/202415:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANNXAnnexon Inc
16/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ANNXAnnexon Inc
12/08/202417:59Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ANNXAnnexon Inc
06/06/202422:57Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANNXAnnexon Inc
16/04/202410:00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:ANNXAnnexon Inc
14/02/202422:46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANNXAnnexon Inc
12/02/202418:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANNXAnnexon Inc
23/01/202419:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANNXAnnexon Inc
07/01/202422:00GlobeNewswire Inc.Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative DiseasesNASDAQ:ANNXAnnexon Inc
27/12/202308:30GlobeNewswire Inc.Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
22/12/202319:28Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ANNXAnnexon Inc
20/12/202319:27GlobeNewswire Inc.Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockNASDAQ:ANNXAnnexon Inc
20/12/202319:24Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ANNXAnnexon Inc
20/12/202319:10GlobeNewswire Inc.Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointNASDAQ:ANNXAnnexon Inc
20/12/202319:08GlobeNewswire Inc.Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayNASDAQ:ANNXAnnexon Inc
18/12/202318:01GlobeNewswire Inc.Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
22/11/202318:01GlobeNewswire Inc.Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ANNXAnnexon Inc
13/11/202308:30GlobeNewswire Inc.Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
09/11/202308:30GlobeNewswire Inc.Annexon Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
24/10/202307:30GlobeNewswire Inc.Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic AtrophyNASDAQ:ANNXAnnexon Inc
10/10/202307:30GlobeNewswire Inc.Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)NASDAQ:ANNXAnnexon Inc
19/09/202307:30GlobeNewswire Inc.Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
18/09/202317:01GlobeNewswire Inc.Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
07/08/202307:30GlobeNewswire Inc.Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANNX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
FICT3
Fictor Alimentos ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
PMAM3
PARANAPANEMA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados